Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies

Current Opinion in Oncology

Volumn 23, Issue 6, 2011, Pages 578-586

  Khokhar, Nushmia Z ^a   Altman, Jessica K ^a   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

kinases; mammalian target of rapamycin; rapalogs; targeted therapy; TORC1; TORC2

Indexed keywords

ALPHA INTERFERON; BENDAMUSTINE; BEVACIZUMAB; BICALUTAMIDE; CARBOPLATIN; CISPLATIN; CLADRIBINE; DOCETAXEL; ERLOTINIB; EVEROLIMUS; EXEMESTANE; GEFITINIB; IMATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OCTREOTIDE; PACLITAXEL; PAZOPANIB; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; RITUXIMAB; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TIVOZANIB; TOPOTECAN; TRASTUZUMAB; UNINDEXED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ASTHENIA; ASTROCYTOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FEVER; DRUG TREATMENT FAILURE; DYSPNEA; EDEMA; ENDOMETRIUM CANCER; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL STROMAL TUMOR; GIANT CELL TUMOR; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NEUROENDOCRINE TUMOR; NEUROPATHY; OSTEOSARCOMA; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 80054099469     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834b892d     Document Type: Review

References (124)

1. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926-1945. (Pubitemid 39071573)
2. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005; 8:179-183. (Pubitemid 41317589)
3. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004; 4:335-348. (Pubitemid 38579480)
4. Caron E, Ghosh S, Matsuoka Y, et al. A comprehensive map of the mTOR signaling network. Mol Syst Biol 2010; 6:453.
5. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6:729-734.
6. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12:9-22. (Pubitemid 47001784)
7. Platanias LC. Mechanisms of type-I-and type-II-interferon-mediated signaling. Nat Rev Immunol 2005; 5:375-386.
8. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008; 27 (Suppl 2):S43-S51.
9. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010; 10:484-495.
10. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-537. (Pubitemid 40613318)
11. Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008; 99:1197-1203.
12. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010; 33:301-311.
13. Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin (mTOR) pathway in hematologic malignancies. Curr Opin Hematol 2008; 15:88-94. (Pubitemid 351323147)
14. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009; 145:569-580.
15. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918. (Pubitemid 41103603)
16. Hudes G, Carducci M, Tomczak P, et al., Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
17. Amato RJ, Jac J, Giessinger S, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009; 115:2438-2446.
18. Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 2010; 28:2131-2136.
19. Motzer RJ, Escudier B, Oudard S, et al., RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
20. Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010; 15:428-435.
21. Faivre S, Raymond E. Mechanism of action of rapalogues: the antiangiogenic hypothesis. Expert Opin Investig Drugs 2008; 17:1619-1621.
22. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms BJU Int 2009; 104:1585-1589.
23. The BeST Trial: a randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma (NCT00378703). http://www.clinicaltrials.gov. [Accessed 25 May 2011]
24. Phase 3b, randomized, open-label study of bevacizumab \+ temsirolimus vs. bevacizumab \+ interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma (NCT00631371). http://www.clinicaltrials.gov. [Accessed 25 May 2011]
25. Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results [meeting abstracts]. J Clin Oncol 2007; 25:5034.
26. Merchan JR, Pitot HC, Qin R. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): safety and activity in RTKI refractory RCC patients. J Clin Oncol 2009; 27:15s (Suppl); abstract 5039.
27. Open label, randomized, multicenter phase II study of a combination of Torisel1 (temsirolimus) and Avastin1 (bevacizumab) versus Sutent1 (sunitinib) and versus a combination of avastin1 (bevacizumab) and Rofé ron1 (interferon alpha-2a) in first-line treatment of patients with metastatic renal cell carcinoma (NCT00619268). http://www.clinicaltrials.gov. [Accessed 25 May 2011]
28. Kabbinavar FF, Srinivas S, Hauke RJ, et al. A phase I trial of combined tivozanib (AV-951) and temsirolimus therapy in patients (pts) with renal cell carcinoma (RCC). J Clin Oncol 2011; 29 (Suppl 7):abstract 330.
29. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab in adult patients with kidney cancer (NCT00719264). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
30. Harzstark AL, Small EJ, Weinberg VK, et al. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer 2011. doi: 10.1002/cncr.25931. [Epub ahead of print]
31. Kroog GS, Feldman DR, Kondagunta GV, et al. Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27:abstract 5037.
32. Efficacy and safety comparison of RAD001 versus sunitinib in the first line and second line treatment of patients with metastatic renal cell carcinoma (NCT00903175). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
33. Sequential two-agent assessment in renal cell carcinoma therapy: the START trial. (NCT01217931). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
34. Pilot study of neo-adjuvant everolimus to treat advanced renal cell carcinoma-analysis of biomarkers. (NCT01107509). http://www.clinical trials.gov. [Accessed in Spring 2011]
35. Everolimus in treating patients with kidney cancer who have undergone surgery (NCT01120249). Available at http://www.clinicaltrials.gov. [Accessed in Spring 2011]
36. Study in nonclear cell renal carcinoma (Ncc-RCC) temsirolimus versus sunitinib (NCT00979966). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
37. Phase II study of afinitor vs. sutent in patients with metastatic nonclear cell renal cell carcinoma (ASPEN). (NCT01108445). http://www. clinicaltrials. gov. [Accessed in Spring 2011]
38. RAD001 for nonclear cell renal cell carcinoma (RCC) (NCT00830895). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
39. Ramalingam SS, Harvey RD, Saba N, et al. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory non small cell lung cancer. Cancer 2010; 116:3903-3909.
40. Price KA, Azzoli CG, Krug LM, et al. Phase II trial of gefitinib and everolimus in advanced nonsmall cell lung cancer. J Thorac Oncol 2010; 5:1623-1629.
41. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26:361-367. (Pubitemid 351171685)
42. A randomized discontinuation phase II trial of deforolimus (ridaforolimus) in nonsmall cell lung cancer (NSCLC) patients with KRAS mutations (NCT00818675). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
43. A phase I study of temsirolimus and thoracic radiation in nonsmall cell lung cancer (NSCLC) (NCT00796796). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
44. Temsirolimus and pemetrexed for recurrent or refractory nonsmall cell lung cancer. (NCT00921310). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
45. Everolimus and whole brain radiation therapy in treating patients with brain metastasis from nonsmall cell lung cancer (NCT00892801). http://www. clinicaltrials.gov. [Accessed in Spring 2011]
46. Safety of everolimus and pemetrexed in lung cancer patients. (NCT00434174). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
47. Pandya KJ, Dahlberg S, Hidalgo M, et al., Eastern Cooperative Oncology Group (E1500). A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007; 2:1036-1041. (Pubitemid 350059580)
48. Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010; 16:5900-5907.
49. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28:69-76.
50. Yao JC, Shah MH, Ito T, et al., RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514-523.
51. Phase I study of anti-IGF-1R monoclonal antibody, IMC-A12, and mTOR inhibitor, everolimus, in advanced low to intermediate grade neuroendocrine carcinoma (NCT01204476). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
52. Chollet P, Abrial C, Tacca, et al. Mammalian target of rapamycin inhibitors in combination with letrozole in breast cancer. Clin Breast Cancer 2006; 7:336-338. (Pubitemid 44717767)
53. ChowL, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1):abstract 6091.
54. Vanderbilt-Ingram Cancer Center. Cisplatin and paclitaxel with or without everolimus in treating patients with stage II or stage III breast cancer (NCT00930930). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
55. Von Minckwitz G, Eidtmann H, Loibl S, et al., German Breast Group and Arbeitsgemeinschaft Gynä kologische Onkologie-Brust investigators. Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011; 22:301-306.
56. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008; 44:84-91. (Pubitemid 350256937)
57. Mayer I, Burris H, Bendell J, et al.Aphase I trial ofweekly cisplatin, paclitaxel and RAD001, anmTOR inhibitor, in patients with HER2-negative metastatic breast cancer [abstract 250]. ASCO Breast Cancer Symposium; October 2009.
58. Gligorov J, Azria D, Namer M, et al. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol 2007; 64:115-128. (Pubitemid 47496223)
59. Migliaccio DB, Gutierrez I, Wu MC, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011; 29:166-173.
60. Esteva FJ, Guo H, Zhang S, et al.PTEN, PIK3CA, p-AKT, and p-p70S6Kstatus: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010; 177:1647-1656.
61. O'Brien NA, Browne BC, ChowL, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010; 9:1489-1502.
62. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pretreated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011; 125:447-455.
63. Everolimus in combination with trastuzumab and paclitaxel in the treatment of HER2 Positive locally advanced or metastatic breast cancer (BOLERO-1). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
64. Daily everolimus in combination with trastuzumab and vinorelbine in HER2/Neu positive women with locally advanced or metastatic breast cancer (BOLERO-3). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
65. Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole (BOLERO-2). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
66. Slomovitz BM, Lu KH, Johnston T, et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus) in patients with recurrent endometrial carcinoma. Cancer 2010; 116:5415-5419.
67. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 2007; 25 (18 Suppl):278s: abstract 5516.
68. Oza AM. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 2008; 26:abstract 5516.
69. Oza AM. Phase I study of temsirolimus (CCI-779), carboplatin, and paclitaxel in patients (pts) with advanced solid tumors: NCIC CTG IND 179. J Clin Oncol 2009; 27 (Suppl. 15):abstract 3558.
70. Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol 2010; 117:473-476.
71. A phase I study of the weekly oral RAD001 in combination with oral topotecan in patients with advanced or recurrent endometrial cancers (NCT00703807). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
72. A randomized phase II trial of ridaforolimus (AP23573; MK-8669) compared to progestin or chemotherapy in female adult patients with advanced endometrial carcinoma (NCT00739830). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
73. Phase II study of RAD001 and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer an investigator-initiated, single-institution trial at Magee-Womens Hospital (NCT01031381). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
74. Study of the mTOR inhibitor temsirolimus (CCI-779) in patients with CA125 only relapse of ovarian cancer. A phase II study by the Hellenic Cooperative Oncology Group (NCT00926107). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
75. A phase II evaluation of temsirolimus (CCI-779) in combination with carboplatin and paclitaxel followed by temsirolimus (CCI-779) consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary. (NCT01196429). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
76. Phase II study of RAD001 and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer an investigator-initiated, single-institution trial at Magee-Womens Hospital. (NCT01031381). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
77. A phase II randomized, double-blinded evaluation of oral everolimus (RAD001) plus bevacizumab vs. oral placebo plus bevacizumab in the treatment of recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer (NCT00886691). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
78. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, et al. Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature. Eur J Neurol 2009; 16:691-696.
79. Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giantcell astrocytomas in tuberous sclerosis. N Engl J Med 2010; 363:1801-1811.
80. Chang SM, Wen P, Cloughesy T, et al., North American Brain Tumor Consortium and the National Cancer Institute. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 2005; 23:357-361. (Pubitemid 40980358)
81. Sarkaria JN, Galanis E, Wu W, et al. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 2010; 16:5573-5580.
82. Blay JY. Updating progress in sarcoma therapy with mTOR inhibitors. Ann Oncol 2011; 22:280-287.
83. Okuno SH. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas. J Clin Oncol 2006; 24 (18Suppl):abstract 9504.
84. Dumez H. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib resistant gastrointestinal stromal tumors (GIST). J Clin Oncol 2008; 26:abstract 10519.
85. Chawla SP, Tolcher AW, Staddon AP, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas: update of phase II trial. J Clin Oncol 2007; 25:abstract 10076.
86. Ridaforolimus in treatment of sarcoma-SUCCEED (8669-011) (NCT00538239). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
87. Altomare I, Russell KB, Uronis HE, et al. Phase II trial of bevacizumab plus everolimus for refractory metastatic colorectal cancer. J Clin Oncol 2010; 28 (15Suppl):abstract 3535.
88. Chen L, Shiah HS, Chen CY, et al. Randomized, phase I, and pharmacokinetic study of RAD001, an mTOR inhibitor, in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009; 27 (15Suppl):abstract 4587.
89. Kelley RK, Nimeiri HS, Vergo MT, et al. A phase I trial of the combination of temsirolimus and sorafenib in advanced hepatocellular carcinoma. J Clin Oncol 2011; 29: (4Suppl):abstract 296.
90. Treiber G, On behalf of the German HCCRADBMSG. Treatment of advanced or metastatic hepatocellular cancer: interim analysis of a singlearm phase II study of bevacizumab and RAD001. J Clin Oncol 2010; 28 (15 Suppl):4102171.
91. Pan C, Ghosh P, Suga JM, et al. Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): early results from a phase I/II clinical trial. J Clin Oncol 2010; 28 (15 Suppl):e15131.
92. An open label study of exploratory pharmacogenomics and pharmacologic effects of neoadjuvant oral temsirolimus in newly diagnosed cancer patients undergoing radical prostatectomy who have a high risk of relapse (NCT00235794). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
93. Phase Ib/II evaluation of RAD001 with docetaxel and bevacizumab in patients with metastatic androgen independent cancer (NCT00574769). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
94. Phase II trial of carboplatin and RAD001 in metastatic castrate resistant prostate cancer (CRPC) pretreated with docetaxel chemotherapy (NCT01051570). http://www.clinicaltrials.gov. [Accessed 25 May 2011]
95. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-5356. (Pubitemid 46206988)
96. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113:508-514.
97. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822-3829.
98. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12:361-368.
99. Rituximab, cladribine and temsirolimus in treating patients with newly diagnosed mantle cell lyphoma (NCT00787969). http://www.clinicaltrials. gov. [Accessed in Spring 2011]
100. Temsirolimus, bedamustine and rituximab for relapsed follicular lymphoma or mantle cell lymphoma. (NCT01078142). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
101. Ré cher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105:2527-2534.
102. Perl AE, Kasner MT, Tsai DE, et al. A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 2009; 15: 6732-6739.
103. Rizzieri DA, Feldman E, Dipersio JF, et al. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2008; 14:2756-2762.
104. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12:5165-5173. (Pubitemid 44453345)
105. Phase I study evaluating the chemosensitizing effect of everolimus administered with cytarabine and daunorubicin in patients with acute myeloid leukemia in relapse. (NCT00544999). http://www.clinicaltrials.gov. [Accessed in Spring 2011]
106. Farag SS, Zhang S, Jansak BS, et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009; 33:1475-1480.
107. Ghobrial IM, Weller E, Vij R, et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011; 12:263-272.
108. Richard DJ, Verheijen JC, Zask A. Recent advances in the development of selective, ATP-competitive inhibitors of mTOR. Curr Opin Drug Discov Devel 2010; 13:428-440.
109. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 2010; 29:3733-3734.
110. Vu C, Fruman DA. Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res 2010; 16:5374-5380.
111. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2:pe24.
112. Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010; 22:169-176.
113. Albert S, Serova M, Dreyer C, et al. New inhibitors of the mammalian target rapamycin signaling pathway for cancer. Expert Opin Investig Drugs 2010; 19:919-930.
114. Hsieh AC, Costa M, Zollo O, et al. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010; 17:249-261.
115. Feldman ME, Apsel B, Uotila A, et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 andmTORC2. PLoS Biol 2009; 7:e38.
116. Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 2009; 23:77-91.
117. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16:205-213.
118. Carayol N, Vakana E, Sassano A, et al. Critical roles for mTORC2-and rapamycin-insensitive mTORC1-complexes in growth and survival of BCRABL-expressing leukemic cells. Proc Natl Acad Sci USA 2010; 107:12469-12474.
119. Altman JK, Sassano A, Kaur S, et al. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011; 17:4378-4388.
120. Hoang B, Frost P, Shi Y, et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116:4560-4568.
121. García-Mart?́nez JM, Wullschleger S, Preston G, et al. Effect of PI3K-and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer 2011; 104:1116-1125.
122. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30:3222-3233.
123. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010; 70:288-298.
124. Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. Cancer Res 2011; 71:1573-1583.